Incellipan (Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/)

Incellipan is an influenza vaccine used to stimulate immune protection against influenza viruses.

• Seasonal influenza (A/Turkey strain): provides active immunization to reduce the risk of infection and related complications.
• Pandemic influenza preparedness: contributes to population immunity against emerging A/Turkey‑like strains.
• High‑risk groups (elderly, chronic disease patients): helps lower incidence of severe influenza outcomes.

• Incellipan contains inactivated influenza virus antigens from the A/Turkey strain, formulated with adjuvants such as squalene and polysorbate 80. After intramuscular injection, the antigens are taken up by antigen‑presenting cells, which process and display viral proteins on MHC molecules. This activates helper T cells and stimulates B‑cell differentiation, leading to production of strain‑specific neutralizing antibodies that confer protective immunity.

Incellipan, like other injectable vaccines, may be associated with a range of adverse reactions following administration.

Common Side Effects

• Injection site pain: mild to moderate soreness at the injection site.
• Redness or swelling: localized erythema or edema.
• Low‑grade fever: transient temperature rise within 24 hours.
• Headache: mild headache occurring shortly after vaccination.
• Fatigue: temporary feeling of tiredness.
• Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurological disorder with muscle weakness.
• Seizures: infrequent convulsive episodes post‑vaccination.
• Severe local reaction: extensive swelling or necrosis at injection site.

Prior to administering Incellipan, healthcare professionals should observe the following precautions to ensure safety and product integrity.

• Contraindication: do not vaccinate individuals with a known severe allergy to any vaccine component.
• Acute illness: postpone vaccination in persons with moderate or severe acute febrile illness.
• Immunocompromised patients: assess risk‑benefit, as response may be reduced.
• Pregnancy: evaluate benefits versus potential risks; limited safety data are available.
• Concomitant vaccines: separate administration by at least 4 weeks from live vaccines.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Incellipan may interact with other agents; awareness of these interactions helps optimize patient care.

Major Interactions (Avoid)

• Immunoglobulin therapy: may neutralize vaccine antigens, reducing efficacy.
• Blood products: concurrent administration can impair immune response.
• Live viral vaccines: avoid simultaneous use due to potential interference.

Moderate Interactions (Monitor Closely)

• Antipyretics (acetaminophen, ibuprofen): may blunt antibody response if given prophylactically.
• Corticosteroids: high‑dose therapy may diminish immunogenicity.
• Antiretroviral therapy: monitor immune status in HIV‑positive patients.